Introduction/Background Since LION trial was published, its concept was implemented in clinical work. Keeping in mind that there is no survival benefit for prophylactic lymphadenectomies, we remove only suspicious lymph nodes (not only pelvic and/or paraaortic) but inguinal, pararectal, mesenteric, gastric, pancreatic, hepatoduodenal and cardiophrenic as well.

Methodology Retrospective analysis of operative reports of patients who received high complexity cytoreductive surgery from 2020 to 2023 years in department of minimally invasive surgery (Kyiv City Clinical Oncology Center). Descriptive statistics was applied.

Results It was identified 124 cases. There were 110 (89%) ovarian cancer patients. Primary debulking surgery was performed in 41 cases (33%), interval debulking surgery – in 48 (39%), redebulking after primary surgery in other center – 4 (3%), secondary cytoreductive surgery – 26 (21%), third cytoreductive surgery – 3 (2%), fourth cytoreductive surgery – 2 (2%). Lymphadenectomy was performed in 70 cases (57%). Metastatic involvement was approved in 41 patients (59%). Pelvic and/or paraaortic lymph nodes were impaired in 34 cases (7 of them were combined with other localizations of lymph nodes metastases), inguinal – 1, pararectal – 2, mesenteric – 4, gastric – 1, pancreatic – 2, hepatoduodenal – 1, cardiophrenic – 4. Pelvic lymph nodes metastases were confirmed in 11 patients, paraaortic – in 9, pelvic and paraaortic – in 14. There were no cases of major intraoperative complications due to lymph nodes removal.

Conclusion Even removing suspicious lymph nodes, we have almost half of patients for whom it wouldn’t be beneficial. Further researches are needed to clarify general criteria for lymphadenectomy (for different regions it may differ) during cytoreductive surgery.

Disclosures none